Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Bristol Myers Squibb (BMS) has announced that its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) has ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Key Takeaways Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

The FDA's latest approval for Breyanzi is based on results from the MCL cohort of TRANSCEND NHL 001, which enrolled patients who had tried at least two lines of therapy, including a BTK inhibitor ...

Breyanzi is obviously late to the CD19 CAR-T field, but BMS hopes its safety profile could differentiate itself from Kymriah and Yescarta, which have built up years of marketing experience.

The efficacy of Breyanzi in the second-line setting was also supported by data from the single-arm, open-label, phase 2 PILOT trial (ClinicalTrials.gov Identifier: NCT03483103), which included 61 ...

“Breyanzi represents a remarkable advance over a nearly 30-year standard of care, providing significantly improved efficacy with a well-established safety profile,” Manali Kamdar, MD, lead ...

The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.Lisocabtagene maraleucel (Breyanzi, Bristol Myers ...